FindTrial
Sign In

nintedanib therapy will improve management in covid 19 fibrosis if given early or not.

Therapy with nintedanib â??Does it improve outcome in patients of Covid-19 pneumonia if given early?

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029783
Enrollment
30
Registered
2020-12-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: NINTEDANIB 150 MG CAPSULE: NINTEDANIB 150 MG CAPSULE TO BE GIVEN BD FOR 12 WEEKS MAXIMUM. Control Intervention1: NA: NA

Sponsors

PRATIMA SINGH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All cases of covid 19 pneumonia detected as COVID positive within CT-severity score >=15 and CORADS-4/5/6

Exclusion criteria

Exclusion criteria: -Patients having other interstitial lung diseases. - Patient having CKD or creatinine clearance -Not fulfilling the criteria for study -Not giving consent for study.

Design outcomes

Primary

MeasureTime frame
Improvement in CT thorax findings(CT severity score).Timepoint: 6WEEKS 12WEEKS.—

Secondary

MeasureTime frame
improvement in CT-severity scoreTimepoint: 6 WEEKS, 12 WEEKS—

Countries

India

Contacts

Public ContactPratima Singh

KALINGA INSTITUTE OF MEDICAL SCIENCES

drppratima@gmail.com8895613285

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026